Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regulating angiogenesis: a new therapeutic strategy

M Gibaldi1

  • 1School of Pharmacy, University of Washington, Seattle 98195, USA.

Journal of Clinical Pharmacology
|November 10, 1998
PubMed
Summary

Angiogenesis, the formation of new blood vessels, is crucial for tumor growth but can be targeted by antiangiogenic therapies. Researchers are also exploring therapeutic angiogenesis to treat cardiovascular and peripheral vascular diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.

Journal of pharmacokinetics and biopharmaceutics·2010
Same author

The pharmacokinetics of penamecillin.

British journal of pharmacology and chemotherapy·2008
Same author

Vaccination updates.

The Western journal of medicine·2000
Same author

Are phytoestrogens a "natural alternative" to estrogen replacement therapy?

The Western journal of medicine·2000
Same author

Prevention and treatment of stroke: where do we stand?

Journal of clinical pharmacology·1998
Same author

Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?

Journal of clinical pharmacology·1998

Area of Science:

  • Biomedical research
  • Oncology
  • Cardiovascular science

Background:

  • Angiogenesis, or new blood vessel formation, is typically dormant after adolescence.
  • Cancerous cells can reactivate angiogenesis, fueling tumor growth and metastasis.
  • Therapeutic angiogenesis is emerging as a potential treatment for ischemic diseases.

Purpose of the Study:

  • To review the dual role of angiogenesis in cancer and cardiovascular disease.
  • To highlight the development of antiangiogenic therapies for cancer.
  • To explore the potential of therapeutic angiogenesis for treating ischemic conditions.

Main Methods:

  • Review of current research on angiogenesis inhibitors and stimulators.
  • Analysis of clinical investigations into antiangiogenic drugs like TNP 470.
  • Examination of studies on reestablishing blood flow in ischemic tissues.

Main Results:

  • Antiangiogenic therapies show promise in limiting tumor growth and metastasis.
  • TNP 470, a fumagillin derivative, is the first angiogenesis inhibitor tested in humans.
  • Tumor-derived compounds are potent angiogenesis inhibitors.
  • Stimulating angiogenesis may offer a biologic bypass for ischemic heart and peripheral vascular diseases.

Conclusions:

  • Angiogenesis is a critical target for both cancer therapy and cardiovascular treatment.
  • Further research into angiogenesis modulation holds significant therapeutic potential.
  • Targeting angiogenesis offers a novel approach to managing complex diseases.

Related Experiment Videos